HRT Management in Perimenopausal PCOS Patients

Introduction to HRT Regimens

The American College of Obstetricians and Gynecologists recommends using transdermal 17β-estradiol (50-100 μg daily) combined with cyclic micronized progesterone (100-200 mg/day for 12-14 days per month) as the preferred HRT regimen for perimenopausal women with PCOS, continuing until at least age 50-51 years 1

Transdermal 17β-estradiol is the mandatory first choice for women with PCOS due to its superior cardiovascular and metabolic profile compared to oral formulations, as recommended by the Endocrine Society 1
The use of transdermal 17β-estradiol provides more beneficial effects on lipid profiles, inflammation markers, and blood pressure, which is critical for PCOS patients with baseline cardiovascular risk, according to the American Heart Association 1

Micronized natural progesterone is the first-line progestogen choice for women with PCOS and an intact uterus, as recommended by the American College of Obstetricians and Gynecologists, due to its more favorable cardiovascular risk profile compared to synthetic progestins 1
The dosing of micronized progesterone is 100-200 mg/day orally for 12-14 days per month, as suggested by the Endocrine Society 1, 2

A sequential/cyclic regimen of continuous estrogen with cyclic progestogen for 12-14 days every 28 days is recommended for perimenopausal women with PCOS, as advised by the American College of Obstetricians and Gynecologists, to provide adequate endometrial protection and allow for withdrawal bleeding 1

The HRT regimen should be continued at least until age 50-51 years, as recommended by the Endocrine Society, to provide cardiovascular and bone protection for women with PCOS transitioning through perimenopause 1, 2
Annual monitoring should include clinical review, cardiovascular risk assessment, and lipid profile and fasting glucose/HbA1c checks, as suggested by the American Heart Association and the American Diabetes Association 1, 3, 4

Hypertension is not a contraindication to HRT in PCOS patients, but transdermal estradiol is strongly preferred, as recommended by the American College of Obstetricians and Gynecologists and the American Heart Association 1, 4
Women with PCOS have baseline increased cardiovascular risk due to insulin resistance, dyslipidemia, and metabolic syndrome, and the choice of transdermal 17β-estradiol with micronized progesterone addresses this concern, according to the Endocrine Society and the American Heart Association 1

Absolute contraindications to HRT include personal history of breast cancer and active venous thromboembolism, as stated by the American College of Obstetricians and Gynecologists and the Endocrine Society 3, 4

Patients should be reassured that HRT in perimenopausal/early menopausal women with PCOS does not carry the same risks as HRT initiated in older postmenopausal women, as advised by the American College of Obstetricians and Gynecologists and the Endocrine Society 3, 4
The absolute risks seen in older women do not apply to perimenopausal women, and early initiation of HRT may provide cardiovascular protection rather than harm, according to the American Heart Association and the Endocrine Society 4, 5